INO Share Slide 25% After Company Prices $75 Million Stock OfferInovio Pharmaceuticals, Inc.BATS:INOKalaGhaziInovio Pharmaceuticals Inc. (NASDAQ: INO) saw its shares fall 25% on Friday after the company announced the pricing of a $75 million public offering at $1.05 per share. The offering represents a significant capital-raising move for the clinical-stage biotechnology company, and the sharp decline in the stock suggests investors reacted negatively to the terms of the deal and the dilution associated with issuing new shares. The gross proceeds from the offering are expected to be approximately $75 million, before deducting underwriting discounts, commissions, and offering expenses. That figure excludes any proceeds that could come from the exercise of the underwriter’s option. In other words, the $75 million represents the base size of the offering, and the final amount raised could vary depending on whether the underwriter exercises its additional allotment and on the usual fees and costs tied to the transaction. Jefferies and Piper Sandler are acting as joint book-running managers for the offering, while H.C. Wainwright & Co. is serving as lead manager. The involvement of these firms is typical for a public equity offering of this kind, and their roles include managing the sale and distribution of the newly issued shares. Inovio focuses on developing and commercializing DNA medicines intended to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. As with many biotechnology companies, the company’s valuation and investor sentiment can be sensitive to financing announcements, especially when new shares are sold at a price that may be below where the stock had recently been trading. A public offering can provide needed capital for research, development, and commercialization efforts, but it can also dilute existing shareholders and put pressure on the share price in the near term. The stock move came ahead of a scheduled update on the company’s financial performance. Inovio previously announced that its third-quarter 2026 financial results will be released after the market close on November 10, 2026. Investors will likely be watching that report for details on the company’s cash position, spending, pipeline progress, and any commentary on how the newly raised capital fits into its broader strategy. Overall, the 25% decline reflects the market’s immediate response to the offering’s size and pricing. For investors, the key questions going forward will be how much capital Inovio ultimately raises, how quickly the company uses that capital, and whether upcoming financial and clinical updates support the company’s longer-term plans.